Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by Stock20on Mar 05, 2019 2:30pm
66 Views
Post# 29445115

Financing is closed. Waiting to update NI 43-101 next week.

Financing is closed. Waiting to update NI 43-101 next week.
Broadway Announces Financing Closed, NI 43-101 Update and Quotation as BGH

OAKVILLE, Ontario, March 04, 2019 (GLOBE NEWSWIRE) -- Broadway Gold Mining Ltd. (“Broadway” or the “Company”) (TSX-V: BRD) (FWB: BGH) (OTCQB: BDWYF) is pleased to announce that it has closed its previously announced non-brokered private placement of securities (the “Offering”). Broadway will file an updated NI 43-101 Report on SEDAR and in the technical section of the Company’s website in the next week. The Company is now quoted as BGH on five exchanges in Germany.

Pursuant to the Offering, the Company issued 6,201,000 units at a price of $0.07 per unit for gross proceeds of $434,070. Each unit is comprised of one share and one-half of one share purchase warrant. Each whole share purchase warrant is exercisable at any time during the 12-month period following the issuance thereof to acquire one common share at a price of $0.15 per share. A finder’s fee of 8% ($22,136) was paid with respect to subscriptions by investors introduced to the Company by finders. All securities issued in connection with the Offering are subject to a restricted period of four months and one day following the issuance thereof. The Offering is subject to the approval of the TSX Venture Exchange. The Company may complete further closings of the Offering; however, there is no assurance it will do so.

Broadway’s updated NI 43-101 will be released in the next week. It includes the following highlights:

  • 35% Cu and 23 grams per tonne (“gpt”) Au from mill settlements* of 2,429 tonnes and 1,342 tonnes, respectively;
  • 25% Cu and 17.8 gpt Au, average grades, from mill settlements of a bulk sample of 13,242 tonnes;
  • 62,230 feet of drilling, 150 holes, with Madison mine-related data now modeled in Vulcan 3D;
  • UG17-05, total length 189 feet, true width approximately 80% of core length, intercepted 24.5 gpt Au + 0.391% Cu over 100 feet, containing 68.6 gpt Au + 0.375% Cu over 15 feet and 82.9 gpt Au + 0.366% Cu over 9 feet;
  • Alteration zoning from propylitic to phyllic that is typical of porphyry systems moving toward mineralized core, in hole C17-24 drilled to a depth of 1,237 feet, which ended in latite porphyry. Exhibiting similar characteristics to the latite porphyry hosted at Barrick’s Golden Sunlight Mine the carbonate-latite porphyry contact was intercepted at 988 feet and exhibits pervasive propylitic alteration at the contact. A zone of phyllic alteration was encountered measuring over 41 feet, from 1,014 to 1,055 feet, consisting of closely spaced quartz-pyrite veinlets and pyrite microveinlets. The pyrite disseminations and blebs are surrounded by a fine-grained gray sulfide, either sphalerite or galena. In places within the core of the phyllic alteration zone, narrow micro breccia and hydrothermal streaming textures can be seen. Hole C17-24 was designed to evaluate a chargeability anomaly identified within a highly prospective part of the property; 
  • Interpreted porphyry mineralization at depth given surface-based strontium/yttrium ratios in combination with statistically significant coincident gold, silver, copper, molybdenum, manganese, lead and zinc over a 2.4-kilometer contact zone, which is based on 571 rock chip, 1,468 soil and 231 retrospective soil samples;
  • Induced polarization and other geophysical surveys that combine data to a depth of 1,680 feet from resistivity, chargeability and magnetics, inclusive of mineralized zones, that identified four resistivity lows, four resistivity highs, seven chargeability highs and two magnetic highs interpreted to be associated with the skarn and porphyry source of the mineralization; and,
  • The Company is permitted for mining and exploration.

Data Verification

  • *Mill settlements mean the grade post mill process; it is the amount of copper and gold per tonne that is recovered, which is used to calculate a royalty.
  • Supervision, organization and splitting of core samples were undertaken by Company personnel. Samples were collected in three-foot intervals from half core samples, catalogued and stored in a secure location. Data verification for this report consisted of taking quarter cuts of core during the QP’s site visit between April 23, 2017 and May 2, 2017. All QP cut samples were kept by the QP and shipped independently for assaying to ALS Mineral Laboratories, Vancouver, BC.

Broadway’s shares are quoted in three currencies (CAD, USD, Euro) and quoted under symbols BRD in Canada, BDWYF in the USA and BGH in Germany.


Bullboard Posts